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Abstract
Background. Haemodialysis with the Hemocontrol bio-
feedback system (HHD) is associated with improved
haemodynamic stability compared with standard haemo-
dialysis (HD) (SHD). Although the beneﬁcial effect of
HHD on haemodynamic stability is generally explained
by its effect on blood volume, we questioned whether
additional factors could play a role. Since HHD is associ-
ated with higher initial dialysate sodium concentrations
and ultraﬁltration (UF) rate, we studied whether the
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beneﬁcial effect of HHD on haemodynamic stability may
be explained by an increased release of the vasoconstric-
tor arginine vasopressin (AVP).
Methods. Fifteen chronic dialysis patients underwent
SHD and HHD in random order. All other treatment
factors were identical and patients served as their own
control. Plasma levels of AVP were measured pre-dialysis,
at 30 and 60 min intra-dialysis and, next, hourly until
completion of the dialysis session.
Results. Plasma AVP levels did not change signiﬁcantly
during SHD, whereas AVP levels rose signiﬁcantly within
30 min after the start of HHD (P < 0.01). AVP levels were
signiﬁcantly higher at 30 and 60 min of HHD in compari-
son with SHD (P < 0.05). Dialysis hypotension occurred
signiﬁcantly less frequent during HHD than during SHD
(P < 0.05).
Conclusions. HHD is associated with higher initial AVP
levels compared with SHD. The enhanced release of the
vasoconstrictor AVP with HHD could contribute to the
lower frequency of dialysis hypotension by facilitating
ﬂuid removal during the ﬁrst part of the dialysis session,
permitting lower UF rates during the second half of the
dialysis session.
Keywords: haemodialysis; Hemocontrol; hypotension; vasopressin
Introduction
Intra-dialytic hypotension occurs in ∼20% of haemodialy-
sis (HD) treatments [1]. Consequences range from transi-
ent symptoms such as nausea, dizziness and muscle
cramps to permanent vascular damage like cerebral infarc-
tion and cardiac ischaemia [2]. Intra-dialytic hypotension
is associated with an increased mortality in HD patients
[3]. The combination of a decrease in blood volume and
an inadequate cardiovascular response to the hypovolae-
mia plays a crucial role in the development of intra-
dialytic hypotension [4–6].
The Hemocontrol biofeedback system is designed to
preserve blood volume by continuously adjusting the dia-
lysate conductivity and the ultraﬁltration (UF) rate in
response to blood volume changes. Various studies have
shown that this system improves intra-dialytic haemo-
dynamic stability [4, 5, 7–11]. The beneﬁcial effect of He-
mocontrol HD (HHD) on haemodynamic stability is
generally explained by its effect on blood volume [9, 10].
However, we and others have previously shown that the
actual blood volume levels in the second half of HHD did
not differ signiﬁcantly between HHD and standard HD
(SHD) [4, 7, 9]. Therefore, other factors than blood
volume must play a role.
Adequate and rapid modiﬁcations of the peripheral
resistance are crucial for the maintenance of haemo-
dynamic stability during HD with UF [12]. The peripheral
resistance is mainly regulated by the renin–angiotensin
system, the sympathetic nervous system and by the
release of vasoconstictors like arginine vasopressin (AVP).
The most potent stimuli to AVP release are increased
plasma osmolality and hypovolaemia [13, 14]. Since
HHD is associated with higher initial dialysate sodium
concentrations and a higher initial UF rate, we questioned
whether the beneﬁcial effect of HHD on haemodynamic
stability may (at least in part) be explained by an in-
creased release of AVP. In this study, we therefore tested
the hypotheses that HHD is associated with higher plasma
AVP levels than SHD with constant dialysate conductivity
and UF rate and that higher plasma AVP levels are associ-
ated with improved haemodynamic stability during HD.
Materials and methods
Patients
Patients from the University Medical Center Groningen and the Dialysis
Center Groningen were eligible for inclusion when they were 18 years or
older, were on a three times a week 4 h HD schedule and had frequent
(in >20% of HD sessions in the previous 4 weeks) episodes of dialysis
hypotension.
Dialysis hypotension was deﬁned as a decrease in systolic blood
pressure ≥30 mmHg in combination with hypotensive symptoms (e.g.
nausea, dizziness, light-headedness, muscle cramps, sweating) or a treat-
ment intervention by the dialysis nurse. Treatment interventions were
deﬁned as temporary interruption of UF, need for Trendelenburg pos-
ition, and/or administration of intravenous ﬂuids.
All patients gave written informed consent to the study protocol and
the study was performed in accordance with the principles of the De-
claration of Helsinki. The study was approved by the local Medical
Ethical Committee.
Study protocol
Each participating patient underwent one SHD and one HHD in random-
ised order. The maximum time interval between the two treatments was
2 weeks. Patients served as their own control. Treatment conditions were
identical during both treatments except for the dialysate sodium concen-
tration that is the major difference between SHD and HHD (vide infra).
Medication use was similar at both treatments as well as the posture
(half-supine) and food intake (light meal) during HD. The measurements
took place at the ﬁrst HD treatment of the week because the UF volume
and the blood volume decreases are most pronounced after the longest
inter-dialytic interval [15].
Blood samples for AVP, sodium, potassium, urea, glucose and osmol-
ality were collected from the arterial line at the initiation of HD, at 30
and 60 min of HD and, thereafter, every hour until completion of the
treatment. Blood sampling for AVP at 240 min of dialysis was performed
before blood re-entry to the patient excluding the possibility of a haemo-
dilution effect on post-dialysis AVP levels. At the same time points of
blood sampling, systolic and diastolic blood pressure, heart rate, the
change in blood volume and the cumulative UF volume were registered.
The blood volume change normalized for UF volume (ΔBV/UF ratio)
was calculated as a surrogate marker of the plasma reﬁll rate. Blood
pressure and heart rate were measured by an automatic oscillometric
monitor that is incorporated in the HD apparatus. Changes in blood
volume were measured by Hemoscan (Gambro-Hospal, Lyon, France).
All patients’ complaints and treatment interventions were registered by
the dialysis nurse.
HD treatment
HD was conducted with a low-ﬂux polysulphon dialyzer on an Integra
Physio HD apparatus (Gambro-Hospal). The UF volume was set to
achieve dry weight at the completion of the HD session. Prescriptions
regarding dry weight were made by the nephrologists during their
weekly visit to the participating patients. Dry weight was evaluated clini-
cally (peripheral oedema, signs of pulmonary congestion, intra-dialytic
and inter-dialytic blood pressure course and muscle cramps) in combi-
nation with the cardio-thoracic ratio on chest radiography. For patients
who were not previously on Hemocontrol, the ideal relative blood
volume trajectory for HHD was derived in the week before the start of
the study by analysing the spontaneous relative blood volume curves in
relation to intra-dialytic blood pressure behaviour, cumulative UF
volume and complaints as described previously [7, 8, 10].
Blood ﬂow and dialysate ﬂow rates were 250–380 mL/min and 500–
700 mL/min, respectively, and for the individual patient identical for
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SHD and HHD. Dialysate temperature was 36.0 or 36.5°C and for the
individual patient identical for both treatments. Dialysate composition
for SHD was: sodium 138 mmol/L, magnesium 0.5 mmol/L, chloride
109 mmol/L, bicarbonate 32 mmol/L, acetate 3.0 mmol/L and glucose
1.0 g/dL. Potassium and calcium varied between 1 and 3 mmol/L and
between 1.25 and 1.50 mmol/L, respectively. Dialysate conductivity in
SHD was 13.9 mS/cm. In HHD, the dialysate composition was identical,
except for the dialysate sodium concentration, which was variable ac-
cording to the concept of HHD. The equivalent conductivity during
HHD was set at 13.8 mS/cm with lower and upper tolerance limits of
13.6 and 14.0 mS/cm, respectively. We chose these settings since it is
our experience that, in most patients, the actual equivalent conductivity
upon completion of HHD is ∼0.1 mS/cm higher than the set equivalent
conductivity. In this way, the actually achieved equivalent conductivity
during HHD was expected to equal the dialysate conductivity in SHD.
Laboratory procedures
Blood samples for the determination of AVP were collected in ethylene-
diaminetetraacetic acid tubes and immediately put on ice. Next, the
samples were centrifuged and stored at −20°C until procession. AVP was
measured by radioimmunoassay following an extraction using octadeca-
silyl-silica (DiaSorin, Stillwater, MN) in the General Clinical Laboratory
of the IJsselland Hospital (Capelle aan de IJssel, The Netherlands). The
assay range was between 0.20 and 4.7 pg/mL with a sensitivity of 0.17
pg/mL with 2.5 mL of plasma. The average duplo coefﬁcients of vari-
ation were 4.27% for the low (0.17–0.40 pg/mL), 4.68% for the inter-
mediate (0.40–1.0 pg/mL) and 3.46% for the high (1.0–8.1 pg/mL)
range, respectively.
Blood samples for the determination of sodium, potassium, urea and
osmolality were collected in heparin-coated tubes. Plasma sodium and
potassium levels were measured with the indirect method of ion-selective
electrode on a Roche Modular (Hitachi, Tokyo, Japan). Urea was
measured with the colorimetric method on a Roche Modular analyser.
Coefﬁcients of variation for plasma levels of sodium, potassium and
urea were 0.8, 1.1 and 2.6%, respectively. Blood glucose levels were
measured with the Precision Xceed (Abbott Diabetes Care, Witney, UK)
with a drop of blood from the arterial line. Plasma osmolality was
measured by freezing-point depression on the Osmostat Osmometer
(Arkray, Kyoto, Japan). The coefﬁcient of variation was 1.0%. Plasma
osmolality was also calculated as 2 × plasma [Na+] + plasma glucose +
plasma urea. Urea is considered an ineffective osmole since it can freely
cross cell membranes [16]. Consequently, changes in plasma urea levels
will not affect AVP release [17]. Therefore, we also calculated the effec-
tive osmolality as 2 × plasma [Na+] + plasma glucose [17].
Statistical analysis
Analyses were performed with GraphPad Prism version 5.0 and SPSS
version 16.0. Normally distributed variables are represented as mean ±
SD, variables with a skewed distribution are represented as median and
interquartile range. Normality was tested with the Shapiro–Wilk test.
Comparisons were made with a paired Student’s t-test, Wilcoxon Signed-
Rank Test or Fisher’s exact test when appropriate. The difference in the
course of the UF rate over time between SHD and HHD was tested by
comparing the hourly average UF volumes by analysis of variance.
P-values of <0.05 (two-tailed) were considered statistically signiﬁcant.
Results
Patients
The patient characteristics are shown in Table 1. The
causes of renal failure were pyelonephritis (n = 1), dia-
betes mellitus (n = 2), hypertension (n = 1), microscopic
polyangiitis (n = 1), anti-glomerular basement membrane
glomerulonephritis (n = 1), urologic cause (n = 2) and
focal segmental glomerulosclerosis (n = 3). In four
patients, the cause of renal failure was unknown.
Total weight loss, UF volume, blood pressure, heart rate
and hypotensive episodes
As shown in Table 2, the total weight loss and UF
volume were comparable for the two treatments. Systolic
and diastolic blood pressure and mean arterial pressure
decreased signiﬁcantly during both treatments (P < 0.05)
(Table 2).
Heart rate did not change signiﬁcantly during
SHD, whereas it increased modestly but signiﬁcantly
(P = 0.049) during HHD (Table 2).
Pre-dialysis systolic and diastolic blood pressure as
well as heart rate did not differ between SHD and HHD
(Table 2). Figure 1 shows the percentage change in blood
pressure and heart rate during dialysis. There were no sig-
niﬁcant differences between SHD and HHD although
there was at trend towards a more stable blood pressure
with HHD compared with SHD at 180 and 240 min of
dialysis (P = 0.14 and P = 0.12 at 180 and 240 min,
respectively).
As shown in Table 2, the maximum decrease in systolic
blood pressure compared with the pre-dialysis value was
greater during SHD than during HHD but the difference
was not statistically signiﬁcant (P = 0.082). Dialysis hypo-
tension occurred in ﬁve patients during SHD and in none
of the patients during HHD (P = 0.042). All episodes of
dialysis hypotension occurred in the third and fourth hour
of HD.
Plasma sodium and osmolality
As shown in Figure 2, pre-dialysis plasma sodium levels
and effective osmolality were identical. During the ﬁrst 2
h of HHD, plasma levels of sodium and effective osmol-
ality were signiﬁcantly higher than during SHD. The
post-dialysis plasma sodium concentration and the effec-
tive plasma osmolality were comparable for SHD and
Table 1. Patient characteristicsa
Characteristics N = 15
Age (years) 56.0 ± 15.5
Dialysis vintage (months) 29.0 ± 20.6
Number of males (%) 10 (67)
Number of diabetics (%) 4 (27)
History of
Hypertension, n (%) 8 (53)
Diastolic dysfunction, n (%) 1 (7)
Atrial ﬁbrillation, n (%) 2 (13)
Aortic stenosis, n (%) 1 (7)
Coronary artery stenosis, n (%) 1 (7)
CVA, n (%) 1 (7)
Medication used
Beta blocker, n (%) 10 (67)
Nitrate, n (%) 2 (13)
CCB, n (%) 1 (7)
ACE-I, n (%) 1 (7)
SSRI/TCA, n (%) 3 (20)
aContinuous variables are represented as mean ± SD. ACE-I, angiotensin
converting enzyme inhibitor; CCB, calcium channel blocker; CVA,
cerebrovascular accident; SSRI, serotonin reuptake inhibitor; TCA,
tricyclic antidepressant.
Enhanced vasopressin release with Hemocontrol 3265






HHD. Results for measured and calculated osmolality
were comparable with the results of effective osmolality
(data not shown). The course of osmolality was compar-
able with or without urea in the calculation of osmolality.
The main determinants of plasma osmolality are plasma
concentrations of sodium, glucose and urea. Pre-dialysis
and intra-dialysis plasma levels of potassium, urea and
glucose were comparable for the two treatments (data not
shown). The difference in effective plasma osmolality
between SHD and HHD was solely caused by the differ-
ence in plasma sodium concentration.
The average UF volume in the ﬁrst hour of HD was
signiﬁcantly higher with HHD compared with SHD (1.20
± 0.22 versus 0.95 ± 0.23 L/h; P < 0.01) and did not differ
signiﬁcantly between HHD and SHD from the second
hour onwards (Figure 3). The total UF volume during the
complete HD session was comparable for both treatments
(Table 2).
The initially higher UF rate with HHD coincided with
a more pronounced fall in the relative blood volume at 30
min of HHD compared with SHD (P < 0.01). From 60
min onwards until the end of the HD session, the relative
blood volume did not differ signiﬁcantly between both
treatments (Figure 3). The course of the ΔBV/UF ratio did
not differ between SHD and HHD (Figure 3).
Vasopressin
As shown in Table 3, pre-dialysis AVP levels did not
differ between HHD and SHD. During SHD, almost no
change in plasma AVP levels was observed (Figure 4).
During HHD, however, plasma AVP levels rose signiﬁ-
cantly and almost doubled within the ﬁrst 30 min of the
HD session. At 30 min and at 60 min of dialysis with
HHD, plasma AVP levels were signiﬁcantly higher in
comparison with SHD (P < 0.01).
Discussion
This study shows that HHD is associated with higher
plasma AVP levels in comparison with SHD. The diver-
gence occurred early during treatment: plasma AVP levels
rose signiﬁcantly within 30 min after the start of HHD,
whereas AVP levels did not rise signiﬁcantly during SHD.
Our ﬁndings of signiﬁcantly less intra-dialytic hypoten-
sion with HHD [4, 5, 7–11, 18] and our observation that
AVP did not increase during SHD [19–25] match previous
ﬁndings. The observation that HHD is associated with an
increase in plasma AVP levels during HD has not been
reported before.
Hyperosmolality and hypovolaemia are powerful
stimuli for AVP release [13, 14]. It follows that the in-
crease in AVP levels during HHD could be related to
the higher plasma osmolality and the more pronounced
hypovolaemia with HHD compared with SHD. The
peak of the AVP response during HHD coincided with
the peak of the effective plasma osmolality and with
the most prominent change in blood volume. The
response of AVP on hypovolaemia and hyperosmolality
occurs within minutes [16] and, therefore, the coinci-
dent dynamics of AVP levels with plasma osmolality
and blood volume changes are compatible with the ex-
pected physiology of AVP release. Another major phys-
iological stimulus for AVP release is hypotension [13,
14]. However, the intra-dialytic blood pressure reduction
during the ﬁrst half of the dialysis did not differ sig-
niﬁcantly between the two treatment modalities and,
Table 2. Pre- and post-dialysis weight, total weight loss, UF volume, blood pressure and heart ratec
SHD, N = 15 HHD, N = 15
Weight (kg)
Pre-HD 79.6 ± 11.6 79.6 ± 11.9
Post-HD 77.0 ± 12.3a 77.0 ± 11.8a
Total weight loss (kg) 2.6 ± 0.9 2.6 ± 0.6
Cumulative UF volume (L) 3.4 ± 0.7 3.3 ± 0.6
SBP (mmHg)
Pre-HD 144.7 ± 15.8 143.0 ± 24.8
Post-HD 121.8 ± 20.6a 127.9 ± 28.4a
Maximum SBP decrease (mmHg) − 36.0 ± 15.3a − 27.1 ± 18.4a
DBP (mmHg)
Pre-HD 83.3 ± 11.4 82.1 ± 12.5
Post-HD 71.4 ± 13.5a 69.0 ± 14.5a
MAP (mmHg)
Pre-HD 103.8 ± 10.9 102.5 ± 15.2
Post-HD 88.2 ± 14.6a 88.7 ± 15.6a
Number of patients with a MAP decrease ≥10 mmHg during HD 15b 10b
HR (bpm)
Pre-HD 78.7 ± 12.5 79.9 ± 11.9
Post-HD 81.0 ± 10.8 82.6 ± 12.3 a
Number of patients with dialysis hypotension 5b 0b
aDenotes P < 0.05 compared with pre-dialysis value.
bDenotes P < 0.05 for the comparison between SHD and HHD.
cContinuous variables are represented as mean ± SD. bpm, beats per minute; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial
pressure; SBP, systolic blood pressure.
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therefore, the early divergence in AVP levels between
SHD and HHD cannot be explained by differences in
blood pressure reduction.
Hyperosmolality as a stimulus for AVP release can
also be induced during SHD by modiﬁcation of the
dialysate sodium concentration using sodium proﬁles
[26]. However, sodium proﬁling during SHD carries the
risk of sodium retention resulting in increased thirst, in-
creased inter-dialytic weight gain and hypertension [27],
whereas Hemocontrol uses controlled sodium modiﬁ-
cations to prevent intra-dialytic sodium loading [4, 5, 7,
9–11, 18].
The beneﬁcial effect of HHD on haemodynamic stab-
ility is generally explained by its effect on blood
volume [9, 10]. Although this and other studies have
shown that the actual blood volume at the end of the
HD session is comparable between HHD and SHD [4,
7, 9], HHD may well favour haemodynamic stability
by preventing sudden blood volume reductions as has
been suggested by Santoro et al. [9]. In the present
study, we have identiﬁed a possible additional expla-
nation for the positive effect of HHD on haemo-
dynamic stability, e.g. an enhanced release of AVP. The
higher plasma levels of the vasoconstrictor AVP early
during HHD may favour haemodynamic stability and,
thus, facilitate relatively high UF rates early during HD,
permitting lower UF rates during the second half of the
dialysis session.
In this study, we found no evidence for a higher
plasma reﬁll rate with HHD compared with SHD.
Santoro et al. reported that the ΔBV normalized for
total weight loss at the end of the dialysis session did
not differ signiﬁcantly between SHD and HHD [5].
However, it should be realised that the ΔBV/UF ratio
provides only a rough estimation of reﬁll. With the use
of a bioimpedance-based estimation of the plasma reﬁll
rate, Basile et al. observed higher reﬁll rates with He-
mocontrol compared with SHD in ﬁve hypotension-
prone patients [7].
Although the ﬁnal change in blood volume was com-
parable between SHD and HHD [4, 7, 9], the blood
volume course differed between SHD and HHD
Fig. 1. Percentage change in systolic (upper panel) and diastolic blood
pressure (middle panel) and heart rate (lower panel) compared with the
pre-dialysis values. Mean ± SD.
Fig. 2. Course of plasma sodium (left panel) and effective plasma osmolality (right panel). Mean ± SD. *Denotes a signiﬁcant difference (P < 0.05)
between SHD and HHD.
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throughout the dialysis session. In accordance with pre-
vious studies, HHD was associated with a more rapid
reduction in blood volume within the ﬁrst hour of dialysis
in comparison with SHD [4, 9, 28]. This is probably ex-
plained by the signiﬁcantly higher initial UF rate with
HHD compared with SHD.
In this study, the pattern of the blood volume course
during the second half of dialysis with HHD was not as
stable as previously reported [4, 9, 28]. This may be
related to the relatively high cumulative UF volume and/
or the use of a lower equivalent conductivity for HHD in
the present study.
From this study, it can be concluded that modifying
the dialysis prescription can increase the AVP release
in dialysis patients. At the same time, it should be
realised that the extent of the increase of AVP levels
with HHD is still rather small given the combination
of stimuli for AVP secretion, i.e. the fall in blood
volume and blood pressure and the increase in effec-
tive osmolality [13].
The question why AVP levels do not increase sub-
stantially during SHD, as shown in the present and
previous studies [19–25] still exists. Several groups
have suggested that autonomic dysfunction may play a
role [19, 21, 29]. Since AVP secretion is under barore-
ﬂex control, it follows that autonomic dysfunction
could impair AVP release. Alternatively, increased
nitric oxide (NO) synthesis induced by HD [30] may
inhibit the release of AVP [19, 31, 32]. Finally,
endogenous AVP release during HD may be underesti-
mated as a result of the removal of AVP (molecular
size 1 kDa) by dialysis, as has been suggested pre-
viously [33]. Further research is needed to investigate
whether this is indeed the case.
The small number of patients and dialysis sessions
studied are limitations of the present study. Therefore,
our results should be conﬁrmed in a larger cohort of
dialysis patients before a deﬁnite conclusion can be
drawn. Although the dialysis settings, medication use,
food and beverage intake and posture during HD were
all standardised in this study, we cannot exclude vari-
ations in inter-dialytic sodium and/or water intake with
associated differences in extracellular and blood
volume between SHD and HHD. However, the ran-
domised cross-over design and the observation that
pre-dialysis weight, plasma sodium levels, plasma os-
molality and AVP levels were comparable between
SHD and HHD make it unlikely that this has affected
our results. We did not measure detailed haemo-
dynamic data like peripheral vascular resistance and
cardiac index. Future studies should preferably assess
the change in AVP levels in relation to the change of
these haemodynamic parameters. A strength of the
present study is the within-subject design where
patients served as their own control.
Conclusion
HD with Hemocontrol is associated with an enhanced
initial rise of the plasma vasopressin concentration com-
pared with SHD. This augmented initial vasopressin
release could contribute to the lower frequency of dialysis
hypotension with Hemocontrol by facilitating ﬂuid
removal during the ﬁrst part of the HD session, permitting
lower UF rates and, consequently, improved haemo-
dynamic stability in the second half of the HD session.
Fig. 3. Total UF volume per hour (upper panel), blood volume change
(middle panel) and blood volume change normalized for intra-dialytic
UF volume (ΔBV/UF ratio; lower panel). Mean ± SD. *Denotes a
signiﬁcant difference (P < 0.05) between SHD and HHD.
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Abstract
Background. Optimal treatment for secondary hyperpar-
athyroidism (SHPT) has not been deﬁned. The IMPACT
SHPT (ClinicalTrials.gov identiﬁer: NCT00977080) study
assessed whether dose-titrated paricalcitol plus sup-
plemental cinacalcet only for hypercalcaemia is superior
to cinacalcet plus low-dose vitamin D in controlling intact
parathyroid hormone (iPTH) levels in patients with SHPT
on haemodialysis.
Methods. In this 28-week, multicentre, open-label Phase 4
study, participants were randomly selected to receive parical-
citol or cinacalcet plus low-dose vitamin D. Randomization
and analyses were stratiﬁed by mode of paricalcitol adminis-
tration [intravenous (IV) or oral]. The primary efﬁcacy end
point was the proportion of subjects who achieved a mean
iPTH value of 150–300 pg/mL during Weeks 21–28.
Results. Of 272 subjects randomized, 268 received one or
more dose of study drug; 101 in the IV and 110 in the oral
stratum with two or more values during Weeks 21–28
were included in the primary analysis. In the IV stratum,
57.7% of subjects in the paricalcitol versus 32.7% in the
cinacalcet group (P = 0.016) achieved the primary end
point. In the oral stratum, the corresponding proportions of
subjects were 54.4% for paricalcitol and 43.4% for cina-
calcet (P = 0.260). Cochran–Mantel–Haenszel analysis,
controlling for stratum, revealed overall superiority of par-
icalcitol (56.0%) over cinacalcet (38.2%; P = 0.010) in
achieving iPTH 150–300 pg/mL during Weeks 21–28. Hy-
percalcaemia occurred in 4 (7.7%) and 0 (0%) of paricalci-
tol-treated subjects in the IV and oral strata, respectively.
Hypocalcaemia occurred in 46.9% and 54.7% of cinacal-
cet-treated subjects in the IVand oral strata, respectively.
Conclusion. Paricalcitol versus cinacalcet plus low-dose
vitamin D provided superior control of iPTH, with low in-
cidence of hypercalcaemia.
Keywords: cinacalcet hydrochloride; paricalcitol; secondary
hyperparathyroidism; kidney disease; haemodialysis
Introduction
Secondary hyperparathyroidism (SHPT), a complication
of chronic kidney disease (CKD), is characterized by
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